Noxopharm Limited (ASX:NOX) confirms that its inaugural clinical study of
experimental anti-cancer product, NOX66, is on schedule to open in December
2016.
The Phase 1a/1b study is being conducted in Georgia and has been cleared by
the 2 selected hospital sites to commence, allowing details of the study to be
posted today on-line.
For further information please download PDF attached:
Download this document
